Q3 2020 EPS Estimates for Myovant Sciences Ltd (NYSE:MYOV) Raised by Analyst

Myovant Sciences Ltd (NYSE:MYOV) – Research analysts at Svb Leerink lifted their Q3 2020 earnings estimates for Myovant Sciences in a research report issued on Wednesday, November 13th. Svb Leerink analyst A. Fadia now forecasts that the company will post earnings of ($0.77) per share for the quarter, up from their prior forecast of ($0.86). Svb Leerink currently has a “Outperform” rating and a $26.00 target price on the stock. Svb Leerink also issued estimates for Myovant Sciences’ Q4 2020 earnings at ($0.73) EPS, FY2020 earnings at ($3.18) EPS, FY2021 earnings at ($2.51) EPS, FY2022 earnings at ($2.52) EPS, FY2023 earnings at ($0.84) EPS and FY2024 earnings at $1.26 EPS.

MYOV has been the topic of several other research reports. Cowen reissued a “buy” rating on shares of Myovant Sciences in a research note on Tuesday, November 12th. Zacks Investment Research lowered shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. ValuEngine raised shares of Myovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Goldman Sachs Group set a $18.00 price target on shares of Myovant Sciences and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Leerink Swann initiated coverage on shares of Myovant Sciences in a research report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $21.89.

Shares of MYOV opened at $6.17 on Monday. The company has a debt-to-equity ratio of 5.88, a quick ratio of 3.42 and a current ratio of 2.79. The company has a market capitalization of $538.64 million, a price-to-earnings ratio of -1.51 and a beta of 0.91. The company’s 50 day simple moving average is $5.19 and its 200 day simple moving average is $8.45. Myovant Sciences has a 1 year low of $4.14 and a 1 year high of $26.02.

Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.07).

A number of hedge funds and other institutional investors have recently bought and sold shares of MYOV. Janus Henderson Group PLC lifted its position in Myovant Sciences by 73.6% in the 2nd quarter. Janus Henderson Group PLC now owns 4,350,335 shares of the company’s stock valued at $39,371,000 after purchasing an additional 1,843,943 shares during the last quarter. Swiss National Bank lifted its position in Myovant Sciences by 134.0% in the 2nd quarter. Swiss National Bank now owns 73,000 shares of the company’s stock valued at $661,000 after purchasing an additional 41,800 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Myovant Sciences by 34.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 112,361 shares of the company’s stock valued at $1,039,000 after purchasing an additional 28,941 shares during the last quarter. Northern Trust Corp acquired a new position in Myovant Sciences during the 2nd quarter valued at about $105,000. Finally, Virtus ETF Advisers LLC acquired a new position in Myovant Sciences during the 2nd quarter valued at about $279,000. Hedge funds and other institutional investors own 40.45% of the company’s stock.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: What is the Bid-Ask Spread?

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.